Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.

Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X and 10 more

Show all authors

Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J, Weng J

Hepatology (Baltimore, Md.)22 Feb 2019Cited by 218 (Europe PMC)

PMID30341767PMCIDPMC6594101DOI10.1002/hep.30320PepBankPUB-30341767

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, add-on liraglutide significantly reduced intrahepatic lipid (MRI-PDFF) over 26 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, adding liraglutide to metformin lowered liver fat over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseIntrahepatic lipid (MRI-PDFF) change
Study
n: not reported in source
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
MRI-PDFF
15.4%
liraglutide, baseline
MRI-PDFF
12.5%
liraglutide, week 26
Source sentences
Summary
MRI-PDFF, VAT, and weight decreased significantly with liraglutide (15.4% ± 5.6% to 12.5% ± 6.4%, P < 0.001; 171.4 ± 27.8 to 150.5 ± 30.8, P = 0.003; 86.6 ± 12.9 kg to 82.9 ± 11.1 kg, P = 0.005, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the MRI-PDFF change from baseline was significantly greater with liraglutide than with insulin glargine.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered liver fat more than insulin glargine did.
Peptide
Liraglutide
Outcome
DecreaseIntrahepatic lipid (MRI-PDFF) change versus insulin glargine
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176705
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the MRI-PDFF change did not differ significantly between liraglutide and sitagliptin.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide and sitagliptin lowered liver fat by a similar amount.
Peptide
Liraglutide
Outcome
No significant changeIntrahepatic lipid (MRI-PDFF) change versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176708
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, add-on liraglutide significantly reduced visceral adipose tissue over 26 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, adding liraglutide to metformin lowered belly organ fat over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue (VAT) change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
MRI-PDFF, VAT, and weight decreased significantly with liraglutide (15.4% ± 5.6% to 12.5% ± 6.4%, P < 0.001; 171.4 ± 27.8 to 150.5 ± 30.8, P = 0.003; 86.6 ± 12.9 kg to 82.9 ± 11.1 kg, P = 0.005, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176702
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, add-on liraglutide significantly reduced body weight over 26 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, adding liraglutide to metformin lowered body weight over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
Body weight
86.6 kg
liraglutide, baseline
Body weight
82.9 kg
liraglutide, week 26
Source sentences
Summary
MRI-PDFF, VAT, and weight decreased significantly with liraglutide (15.4% ± 5.6% to 12.5% ± 6.4%, P < 0.001; 171.4 ± 27.8 to 150.5 ± 30.8, P = 0.003; 86.6 ± 12.9 kg to 82.9 ± 11.1 kg, P = 0.005, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176703
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, add-on liraglutide significantly reduced subcutaneous adipose tissue over 26 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, adding liraglutide to metformin lowered fat under the skin over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous adipose tissue (SAT) change
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
SAT decreased significantly in the liraglutide group (239.9 ± 69.0 to 211.3 ± 76.1; P = 0.020)
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176704
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the VAT change from baseline was significantly greater with liraglutide than with insulin glargine.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered belly organ fat more than insulin glargine did.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue change versus insulin glargine
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176706
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the body weight change from baseline was significantly greater with liraglutide than with insulin glargine.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered body weight more than insulin glargine did.
Peptide
Liraglutide
Outcome
DecreaseBody weight change versus insulin glargine
Study
n: not reported in source
Comparator
Insulin glargine
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176707
09HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the VAT change did not differ significantly between liraglutide and sitagliptin.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide and sitagliptin changed belly organ fat by a similar amount.
Peptide
Liraglutide
Outcome
No significant changeVisceral adipose tissue change versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176709
10HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and NAFLD on metformin, the body weight change did not differ significantly between liraglutide and sitagliptin.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide and sitagliptin changed body weight by a similar amount.
Peptide
Liraglutide
Outcome
No significant changeBody weight change versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Changes from baseline in MRI-PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on liraglutide, sitagliptin, or insulin…
Report a problemFND-3034176710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms